(-)-Epigallocatechin gallate selectively inhibits adenosine diphosphate‑stimulated human platelet activation: Suppression of heat shock protein 27 phosphorylation via p38 mitogen‑activated protein kinase

Iida,Yuko; Doi,Tomoaki; Matsushima-Nishiwaki,Rie; Tokuda,Haruhiko; Ogura,Shinji; Kozawa,Osamu; Iida,Hiroki

doi:10.3892/mmr.2014.2389

(-)-Epigallocatechin gallate selectively inhibits adenosine diphosphate‑stimulated human platelet activation: Suppression of heat shock protein 27 phosphorylation via p38 mitogen‑activated protein kinase

Authors:
- Yuko Iida
- Tomoaki Doi
- Rie Matsushima-Nishiwaki
- Haruhiko Tokuda
- Shinji Ogura
- Osamu Kozawa
- Hiroki Iida
View Affiliations

Affiliations: Department of Anesthesiology, Gifu University Graduate School of Medicine, Gifu, Gifu 501-1194, Japan, Department of Emergency and Disaster Medicine, Gifu University Graduate School of Medicine, Gifu, Gifu 501-1194, Japan, Department of Pharmacology, Gifu University Graduate School of Medicine, Gifu, Gifu 501-1194, Japan
Published online on: July 16, 2014 https://doi.org/10.3892/mmr.2014.2389
Pages: 1383-1388

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

(‑)‑Epigallocatechin gallate (EGCG) is a major component of green tea. It has been demonstrated that EGCG has an antithrombotic effect by inhibiting platelet aggregation. However, the detailed mechanisms underlying the effects of EGCG remain to be elucidated. The present study examined the effects of EGCG on human platelet activation by various stimulators and the exact underlying mechanisms. EGCG suppressed adenosine diphosphate (ADP)‑stimulated platelet aggregation dose dependently between 30 and 70 µM. By contrast, EGCG failed to affect platelet aggregation stimulated by collagen, U46619 (a TP agonist) or ristocetin (an activator of GPIb/IX/V). EGCG attenuated the ADP‑induced phosphorylation of p38 mitogen‑activated protein (MAP) kinase and heat shock protein 27 (HSP27). The ADP‑stimulated release of platelet‑derived growth factor (PDGF)‑AB and the soluble CD40 (sCD40) ligand was inhibited by EGCG. These findings suggest that EGCG selectively inhibits ADP‑stimulated human platelet activation and that EGCG reduces the release of PDGF‑AB and the sCD40 ligand due to suppressing HSP27 phosphorylation via p38 MAP kinase.

View Figures

View References

1	Jankun J, Selman SH, Swiercz R and Skrzypczak-Jankun E: Why drinking green tea could prevent cancer. Nature. 387:5611997. View Article : Google Scholar : PubMed/NCBI
2	Kang WS, Lim IH, Yuk DY, et al: Antithrombotic activities of green tea catechins and (−)-epigallocatechin gallate. Thromb Res. 96:229–237. 1999.
3	Oyama J, Maeda T, Kouzuma K, et al: Green tea catechins improve human forearm endothelial dysfunction and have antiatherosclerotic effects in smokers. Circ J. 74:578–588. 2010. View Article : Google Scholar
4	Harborne JB and Williams CA: Advances in flavonoid research since 1992. Phytochemistry. 55:418–504. 2000. View Article : Google Scholar
5	Ruggeri ZM: The role of von Willebrand factor in thrombus formation. Thromb Res. 120:S5–S9. 2007. View Article : Google Scholar : PubMed/NCBI
6	Berndt MC, Shen Y, Dopheide SM, Gardiner EE and Andrews RK: The vascular biology of the glycoprotein Ib-IX-V complex. Thromb Haemost. 86:178–188. 2001.PubMed/NCBI
7	Garcia A, Quinton TM, Dorsam RT and Kunapuli SP: Src family kinase-mediated and Erk-mediated thromboxane A2 generation are essential for VWF/GPIb-induced fibrinogen receptor activation in human platelets. Blood. 106:3410–3414. 2005. View Article : Google Scholar
8	Jennings LK: Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis. Thromb Haemost. 102:248–257. 2009.
9	Dong JF, Berndt MC, Schade A, McIntire LV, Andrews RK and López JA: Ristocetin-dependent, but not botrocetin-dependent, binding of von Willebrand factor to the platelet glycoprotein Ib-IX-V complex correlates with shear-dependent interactions. Blood. 97:162–168. 2001. View Article : Google Scholar
10	Hechler B, Léon C, Vial C, Vigne P, Frelin C, Cazenave JP and Gachet C: The P2Y1 receptor is necessary for adenosine 5′-diphosphate-induced platelet aggregation. Blood. 92:152–159. 1998.
11	Daniel JL, Dangelmaier C, et al: Role of intracellular signaling events in ADP-induced platelet aggregation. Thromb Haemost. 82:1322–1326. 1999.PubMed/NCBI
12	Kato H, Takai S, Matsushima-Nishiwaki R, Adachi S, Minamitani C, Otsuka T, Tokuda H, Akamatsu S, Doi T, Ogura S and Kozawa O: HSP27 phosphorylation is correlated with ADP-induced platelet granule secretion. Arch Biochem Biophys. 475:80–86. 2008. View Article : Google Scholar : PubMed/NCBI
13	Doi T, Adachi S, Matsushima-Nishiwaki R, Kato H, Enomoto Y, Minamitani C, Otsuka T, Tokuda H, Akamatsu S, Iwama T, Kozawa O and Ogura S: Antithrombin III suppresses ADP-induced platelet granule secretion: inhibition of HSP27 phosphorylation. Arch Biochem Biophys. 489:62–67. 2009. View Article : Google Scholar : PubMed/NCBI
14	Enomoto Y, Adachi S, Matsushima-Nishiwaki R, Doi T, Niwa M, Akamastu S, Tokuda H, Ogura S, Yoshimura S, Iwama T and Kozawa O: Thromboxane A(2) promotes soluble CD40 ligand release from human platelets. Atherosclerosis. 209:415–421. 2010. View Article : Google Scholar : PubMed/NCBI
15	Jin YR, Im JH, Park ES, Cho MR, Han XH, Lee JJ, Lim Y, Kim TJ and Yun YP: Antiplatelet activity of epigallocatechin gallate is mediated by the inhibition of PLCgamma2 phosphorylation, elevation of PGD2 production, and maintaining calcium-ATPase activity. J Cardiovasc Pharmacol. 51:45–54. 2008. View Article : Google Scholar
16	Fabre JE, Nguyen M, Latour A, Keifer JA, Audoly LP, Coffman TM and Koller BH: Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice. Nat Med. 5:1199–1202. 1999. View Article : Google Scholar : PubMed/NCBI
17	Kato K, Ito H, Hasegawa K, Inaguma Y, Kozawa O and Asano T: Modulation of the stress-induced synthesis of hsp27 and αB-crystallin by cyclic AMP in C6 rat glioma cells. J Neurochem. 66:946–950. 1996.
18	Laemmli UK: Cleavage of structural proteins during assembly of the head of bacteriophage T4. Nature. 227:680–685. 1970. View Article : Google Scholar : PubMed/NCBI
19	Liu J, Pestina TI, Berndt MC, Steward SA, Jackson CW and Gartner TK: The roles of ADP and TXA2 in botrocetin/VWF-induced aggregation of washed platelets. J Thromb Haemost. 2:2213–2222. 2004. View Article : Google Scholar : PubMed/NCBI
20	Nakahata N: Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharmacology. Pharmacol Ther. 118:18–35. 2008. View Article : Google Scholar : PubMed/NCBI
21	Rendu F and Brohard-Bohn B: The platelet release reaction: granules’ constituents, secretion and functions. Platelets. 12:261–273. 2001.
22	Heldin CH and Westermark B: Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev. 79:1283–1316. 1999.PubMed/NCBI
23	Hermann A, Rauch BH, Braun M, Schrör K and Weber AA: Platelet CD40 ligand (CD40L) - subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets. 12:74–82. 2001. View Article : Google Scholar : PubMed/NCBI
24	André P, Nannizzi-Alaimo L, Prasad SK and Phillips DR: Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation. 106:896–899. 2002.PubMed/NCBI
25	Henn V, Slupsky JR, Gräfe M, Anagnostopoulos I, Förster R, Müller-Berghaus G and Kroczek RA: CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 391:591–594. 1998. View Article : Google Scholar : PubMed/NCBI
26	Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM and Simoons ML; CAPTURE Study Investigators. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med. 348:1104–1111. 2003. View Article : Google Scholar : PubMed/NCBI